Tetraphase Pharmaceuticals Stock News

Buy TTPH

*Your capital is at risk

$2.20

+0 (+0%)

At Close: Sep 04, 2020

Tetraphase Announces Second Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased Consideration

12:00am, Friday, 29'th May 2020

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline f

Tetraphase Announces Determination of Superior Offer and Notice to AcelRx

12:00am, Friday, 22'nd May 2020

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline Xerava™ (eravacycline fo

Tetraphase Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call

08:00am, Tuesday, 05'th Nov 2019

WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing novel tetracyclines to treat serious and life-threatening cond

Tetraphase Pharmaceuticals to Host Second Quarter 2019 Financial Results Conference Call

07:00am, Thursday, 01'st Aug 2019

Tetraphase Pharmaceuticals to Host First Quarter 2019 Financial Results Conference Call

07:03am, Wednesday, 01'st May 2019

WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-t

Tetraphase Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Financial Results Conference Call

04:03pm, Thursday, 07'th Mar 2019

Tetraphase Announces Positive Top-line Results from Phase 3 IGNITE 1 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections

04:01pm, Wednesday, 17'th Dec 2014

WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant

Tetraphase Pharmaceuticals Announces Positive Oral Dosing Data from Lead-in of IGNITE 2 Phase 3 Trial of Eravacycline in cUTI Support Advancement to Pivotal Portion

04:01pm, Tuesday, 02'nd Sep 2014

WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that positive top-line results from the lead-in portion of its IGNITE 2 clinical trial, a two-part Pha

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by